Clinical Trial Update: A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing tislelizumab plus concurrent chemoradiotherapy versus placebo with chemoradiotherapy in localized esophageal squamous cell carcinoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Status: COMPLETED | Results posted: 2026-04-13